Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17304275 | 0.95 | TSHR (0.36) | GPR119TSHR | |
| SCHEMBL56080 | 0.95 | TSHR (0.36) | GPR119TSHR | |
| SCHEMBL31032139 | 0.85 | TSHR (0.33) | TSHR | |
| SCHEMBL8181997 | 0.82 | OPRK1 (0.33) | — | |
| SCHEMBL3658994 | 0.80 | KCNH2 (0.38) | KCNH2 | |
| SCHEMBL126707 | 0.80 | — | — | |
| SCHEMBL31570408 | 0.79 | MAPT (0.32) | MAPTGAA | |
| SCHEMBL26444547 | 0.79 | — | — | |
| SCHEMBL5298646 | 0.78 | HSD11B1 (0.33) | TSHR | |
| SCHEMBL17729357 | 0.77 | GPR119 (0.32) | GPR119KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007004226-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF MALE ERECTILE DYSFUNCTION (ED) | DARLEY PHARMACUETICALS LTD. (IL) | 2007-01-11 | — | — | WO | claimed |
| US-12404295-B2 | (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-09-02 | — | — | US | disclosed |
| US-20220315619-A1 | (HETERO)ARYL-METHYL-THIO-BETA-D-GALACTOPYRANOSIDE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-10-06 | — | — | US | disclosed |
| WO-2007004226-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF MALE ERECTILE DYSFUNCTION (ED) | DARLEY PHARMACUETICALS LTD. (IL) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315619-A1 | (HETERO)ARYL-METHYL-THIO-BETA-D-GALACTOPYRANOSIDE DERIVATIVES | LGALS1, LGALS3, LGALS2 | GPR119 192/4885TSHR 342/4885KCNH2 4049/4885 |
| US-12404295-B2 | (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives | LGALS1, LGALS3, LGALS2 | GPR119 192/4885TSHR 342/4885KCNH2 4049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.